Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.

Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.

Diabetic Foot Ulcer

Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.

Deferoxamine

Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.

Placebo

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers

number of patients who have intact skin healing

the number of patients who have ulcer healing improvement of > 50%

Sergiu Catrina

Associated professor

Karolinska University Hospital

prospective, randomised, double-blind and placebo-controlled study with parallel groups, multiple centre trial.

The drugs (active or placebo) will be supplied by the supervision of Medigelium AB and will have the same appearance.

Carnitine Palmitoyl Transferase Type 1A (CPT1A) Deficiency

Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.

hypoglycemia/proliini

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers

Metabolic Consequences of CPT-1 Deficiency

Täydellisin lääketieteellinen tietokanta tieteen tukemana